Abstract
This cohort study examines the association between use of 5α-reductase inhibitors and prostate cancer mortality among US Medicare beneficiaries.
Highlights
Median adjusted prostate-specific antigen (PSA) level at diagnosis was significantly higher in 5α-reductase inhibitor (5-ARI) users compared with nonusers (14.2 [9.0-24.0] ng/mL vs 6.6 [4.8-10.2] ng/mL; difference, 7.6 ng/mL; 95% CI, 7.0-8.2 ng/mL; P < .001 [to convert to micromoles per liter, multiply by 1.0]) (Table 1)
This cohort study found that 5-ARI users presented with higher adjusted PSA levels and prostate cancer (PC) disease burden
They had worse PC-specific mortality (PCSM) and all-cause mortality (ACM), but not worse noncancer mortality. These results are consistent with our recently published findings[3] that observed that among US veterans, 5-ARI use was associated with worse PCSM and ACM (HR, 1.10; 95% CI, 1.05-1.15; P < .001)
Summary
5α-reductase inhibitors (5-ARIs) are used to treat benign prostatic enlargement, a common condition causing urinary outflow obstruction.[1]. Author affiliations and article information are listed at the end of this article
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
